Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SD-101 Cream in Patients With Epidermolysis Bullosa
NCT07482787Phase 3Recruiting
- Sponsor
- Paradigm Therapeutics, Inc.
- Start
- Jul 2026
- Primary completion
- May 2027
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 3 trial of nelitolimod in epidermolysis bullosa (EB), sponsored by Paradigm Therapeutics, Inc.. Started Jul 2026; status: recruiting.
02
Drugs
nelitolimod
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NCT07482787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07482787.